A Seattle-based privately held biotechnology company identifying and developing therapeutic compounds for the treatment of human disease, founded in 1995, Icogen was renamed Icogenex in 2003. The Company's operations have been financed through investments, contracts, and grant support from the National Institutes of Health. The Company has received 13 SBIR Phase I awards, 4 SBIR Phase II awards, an R21, and an R01 award. The 10 successfully completed contract research projects with biotechnology and pharmaceutical companies have demonstrated a proven track record of meeting drug development milestones and timelines. The successful collaborative contract research projects with HemeBiotech (now called Zymenex) included porphobilinogen deaminase which lead to a successful Phase I clinical trial, alpha-mannosidase to successful preclinical trial, and arylsulfatase A to successful Phase II clinical trial resulting in the sale of the project by Zymenex to Shire PLC for $135 million.